NZ198748A - Piperidine derivatives and pharmaceutical compositions - Google Patents
Piperidine derivatives and pharmaceutical compositionsInfo
- Publication number
- NZ198748A NZ198748A NZ198748A NZ19874881A NZ198748A NZ 198748 A NZ198748 A NZ 198748A NZ 198748 A NZ198748 A NZ 198748A NZ 19874881 A NZ19874881 A NZ 19874881A NZ 198748 A NZ198748 A NZ 198748A
- Authority
- NZ
- New Zealand
- Prior art keywords
- radical
- general formula
- piperidine
- alkyl
- acid addition
- Prior art date
Links
- 150000003053 piperidines Chemical class 0.000 title claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 22
- -1 alkoxycarbonyl radical Chemical class 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 150000003254 radicals Chemical class 0.000 claims description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- KRTGJZMJJVEKRX-UHFFFAOYSA-N 2-phenylethan-1-yl Chemical compound [CH2]CC1=CC=CC=C1 KRTGJZMJJVEKRX-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- QIWNOVRXWQPVIY-UHFFFAOYSA-N propylbenzene Chemical compound [CH2]CCC1=CC=CC=C1 QIWNOVRXWQPVIY-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical class O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 59
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 22
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 3
- 206010015995 Eyelid ptosis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028347 Muscle twitching Diseases 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- VNEBWJSWMVTSHK-UHFFFAOYSA-L disodium;3-hydroxynaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=CC2=C1 VNEBWJSWMVTSHK-UHFFFAOYSA-L 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 201000003004 ptosis Diseases 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- GKGCPWOZAGTHMX-UHFFFAOYSA-N (4-hydroxypiperidin-1-yl)-(4-nitrophenyl)methanone Chemical compound C1CC(O)CCN1C(=O)C1=CC=C([N+]([O-])=O)C=C1 GKGCPWOZAGTHMX-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 2
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- VEXLZSWFSWYAON-UHFFFAOYSA-N (4-chlorophenyl)-(4-hydroxypiperidin-1-yl)methanone Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(Cl)C=C1 VEXLZSWFSWYAON-UHFFFAOYSA-N 0.000 description 1
- UNOWCXQLPMFMSW-UHFFFAOYSA-N (4-chlorophenyl)-[4-[(3,4,5-trimethoxyphenyl)methoxy]piperidin-1-yl]methanone Chemical compound COC1=C(OC)C(OC)=CC(COC2CCN(CC2)C(=O)C=2C=CC(Cl)=CC=2)=C1 UNOWCXQLPMFMSW-UHFFFAOYSA-N 0.000 description 1
- STGNLGBPLOVYMA-MAZDBSFSSA-N (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O STGNLGBPLOVYMA-MAZDBSFSSA-N 0.000 description 1
- FXNSRODXMVUCNJ-TYYBGVCCSA-N (e)-but-2-enedioic acid;hydrochloride Chemical compound Cl.OC(=O)\C=C\C(O)=O FXNSRODXMVUCNJ-TYYBGVCCSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- AFQWTJFPNZJKGL-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-4-[(3,4,5-trimethoxyphenyl)methoxy]piperidine Chemical compound COC1=C(OC)C(OC)=CC(COC2CCN(CC=3C=CC(Cl)=CC=3)CC2)=C1 AFQWTJFPNZJKGL-UHFFFAOYSA-N 0.000 description 1
- HKWRVHLLZSIWAR-UHFFFAOYSA-N 4-[(4-fluorophenyl)methoxy]piperidine Chemical compound C1=CC(F)=CC=C1COC1CCNCC1 HKWRVHLLZSIWAR-UHFFFAOYSA-N 0.000 description 1
- TYZNPXDFDHBMNU-UHFFFAOYSA-N 4-phenylmethoxypiperidine;hydrochloride Chemical compound Cl.C=1C=CC=CC=1COC1CCNCC1 TYZNPXDFDHBMNU-UHFFFAOYSA-N 0.000 description 1
- XXRUQNNAKXZSOS-UHFFFAOYSA-N 5-(chloromethyl)-1,2,3-trimethoxybenzene Chemical compound COC1=CC(CCl)=CC(OC)=C1OC XXRUQNNAKXZSOS-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- XVRAODOSQLKMIW-UHFFFAOYSA-N C(C(O)C1=CC=CC=C1)(=O)O.FC1=CC=C(COC2CCNCC2)C=C1 Chemical compound C(C(O)C1=CC=CC=C1)(=O)O.FC1=CC=C(COC2CCNCC2)C=C1 XVRAODOSQLKMIW-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WGIFUQXAAHCOJU-UHFFFAOYSA-N [4-[(4-fluorophenyl)methoxy]piperidin-1-yl]-(4-nitrophenyl)methanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCC(OCC=2C=CC(F)=CC=2)CC1 WGIFUQXAAHCOJU-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960002888 oxitriptan Drugs 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ198748A NZ198748A (en) | 1981-10-23 | 1981-10-23 | Piperidine derivatives and pharmaceutical compositions |
DK469381A DK157853C (da) | 1981-10-23 | 1981-10-23 | Analogifremgangsmaade til fremstilling af 4-benzyloxypiperidinderivater |
JP56170536A JPS5872565A (ja) | 1981-10-23 | 1981-10-23 | ピペリジン誘導体およびその製造方法 |
PT73875A PT73875B (fr) | 1981-10-23 | 1981-10-23 | Procede de preparation de derives de piperidine applicables en therapeutique |
AU76769/81A AU545739B2 (en) | 1981-10-23 | 1981-10-23 | Piperidine derivatives |
FI813330A FI77850C (fi) | 1981-10-23 | 1981-10-23 | Foerfarande foer framstaellning av 4-bensyloxi- eller 4-naftylmetoxipiperidinderivat, vilka har antidepressiv verkan. |
NO813577A NO153890C (no) | 1981-10-23 | 1981-10-23 | Analogifremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater. |
ES506500A ES506500A0 (es) | 1981-10-23 | 1981-10-23 | Procedimiento de preparacion de derivados de piperidina |
GR66337A GR75364B (enrdf_load_html_response) | 1981-10-23 | 1981-10-23 | |
IE2500/81A IE51707B1 (en) | 1981-10-23 | 1981-10-23 | Piperidine derivatives,their preparation and pharmaceutical compositions containing them |
ZA817373A ZA817373B (en) | 1981-10-23 | 1981-10-23 | Piperidine derivatives,their preparation and pharmaceutical compositions containing them |
CA000388595A CA1173039A (en) | 1981-10-23 | 1981-10-23 | 4-benzyloxypiperidine compounds |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ198748A NZ198748A (en) | 1981-10-23 | 1981-10-23 | Piperidine derivatives and pharmaceutical compositions |
DK469381A DK157853C (da) | 1981-10-23 | 1981-10-23 | Analogifremgangsmaade til fremstilling af 4-benzyloxypiperidinderivater |
JP56170536A JPS5872565A (ja) | 1981-10-23 | 1981-10-23 | ピペリジン誘導体およびその製造方法 |
PT73875A PT73875B (fr) | 1981-10-23 | 1981-10-23 | Procede de preparation de derives de piperidine applicables en therapeutique |
AU76769/81A AU545739B2 (en) | 1981-10-23 | 1981-10-23 | Piperidine derivatives |
FI813330A FI77850C (fi) | 1981-10-23 | 1981-10-23 | Foerfarande foer framstaellning av 4-bensyloxi- eller 4-naftylmetoxipiperidinderivat, vilka har antidepressiv verkan. |
NO813577A NO153890C (no) | 1981-10-23 | 1981-10-23 | Analogifremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater. |
ES506500A ES506500A0 (es) | 1981-10-23 | 1981-10-23 | Procedimiento de preparacion de derivados de piperidina |
GR66337A GR75364B (enrdf_load_html_response) | 1981-10-23 | 1981-10-23 | |
IE2500/81A IE51707B1 (en) | 1981-10-23 | 1981-10-23 | Piperidine derivatives,their preparation and pharmaceutical compositions containing them |
ZA817373A ZA817373B (en) | 1981-10-23 | 1981-10-23 | Piperidine derivatives,their preparation and pharmaceutical compositions containing them |
CA000388595A CA1173039A (en) | 1981-10-23 | 1981-10-23 | 4-benzyloxypiperidine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ198748A true NZ198748A (en) | 1984-08-24 |
Family
ID=27582840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ198748A NZ198748A (en) | 1981-10-23 | 1981-10-23 | Piperidine derivatives and pharmaceutical compositions |
Country Status (12)
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02148948U (enrdf_load_html_response) * | 1989-05-17 | 1990-12-18 | ||
US5169855A (en) * | 1990-03-28 | 1992-12-08 | Du Pont Merck Pharmaceutical Company | Piperidine ether derivatives as psychotropic drugs or plant fungicides |
JPH0535676U (ja) * | 1991-06-06 | 1993-05-14 | 株式会社カネマス | 乾燥海草の水戻し用パツク |
-
1981
- 1981-10-23 PT PT73875A patent/PT73875B/pt unknown
- 1981-10-23 JP JP56170536A patent/JPS5872565A/ja active Granted
- 1981-10-23 NO NO813577A patent/NO153890C/no unknown
- 1981-10-23 GR GR66337A patent/GR75364B/el unknown
- 1981-10-23 CA CA000388595A patent/CA1173039A/en not_active Expired
- 1981-10-23 FI FI813330A patent/FI77850C/fi not_active IP Right Cessation
- 1981-10-23 ES ES506500A patent/ES506500A0/es active Granted
- 1981-10-23 IE IE2500/81A patent/IE51707B1/en not_active IP Right Cessation
- 1981-10-23 AU AU76769/81A patent/AU545739B2/en not_active Ceased
- 1981-10-23 DK DK469381A patent/DK157853C/da not_active IP Right Cessation
- 1981-10-23 NZ NZ198748A patent/NZ198748A/en unknown
- 1981-10-23 ZA ZA817373A patent/ZA817373B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PT73875A (fr) | 1981-11-01 |
DK157853B (da) | 1990-02-26 |
DK469381A (da) | 1983-04-24 |
IE812500L (en) | 1983-04-21 |
ES8206476A1 (es) | 1982-08-16 |
ES506500A0 (es) | 1982-08-16 |
AU545739B2 (en) | 1985-08-01 |
CA1173039A (en) | 1984-08-21 |
GR75364B (enrdf_load_html_response) | 1984-07-13 |
IE51707B1 (en) | 1987-02-18 |
DK157853C (da) | 1990-08-06 |
NO153890C (no) | 1986-06-11 |
PT73875B (fr) | 1983-01-25 |
FI77850B (fi) | 1989-01-31 |
ZA817373B (en) | 1983-03-30 |
FI813330L (fi) | 1983-04-24 |
AU7676981A (en) | 1983-04-28 |
FI77850C (fi) | 1989-05-10 |
NO813577L (no) | 1983-04-25 |
JPS5872565A (ja) | 1983-04-30 |
NO153890B (no) | 1986-03-03 |
JPS6135177B2 (enrdf_load_html_response) | 1986-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4007196A (en) | 4-Phenylpiperidine compounds | |
Boido et al. | Synthesis and preliminary pharmacological evaluation of some cytisine derivatives | |
US4939137A (en) | Ring-fused thienopyrimidinedione derivatives | |
US4460598A (en) | Triphenylimidazolyloxyalkanoic acids and their derivatives and a process for the treatment of thromboembolic, inflammatory and/or atheriosclerotic diseases | |
HK16288A (en) | Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them | |
JPS6185362A (ja) | 新規ジアリール化合物 | |
CZ288909B6 (cs) | Difenylmethylenpiperidinový derivát a farmaceutický prostředek s jeho obsahem | |
US5334720A (en) | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties | |
IE832058L (en) | 1,4-dihydropyridine derivatives | |
US4529730A (en) | Piperidine derivatives, their preparation and pharmaceutical compositions containing them | |
WO2014005421A1 (zh) | 苯并间二氧杂环戊烯衍生物及其制备方法和用途 | |
US3983239A (en) | Hexahydro-γ-carboline derivatives and their salts | |
SU1342415A3 (ru) | Способ получени производных пиридазина | |
CS214796B2 (en) | Method of making the new derivatives of 4-amino-2-piperidinochinazoline | |
DK149133B (da) | Analogifremgangsmaade til fremstilling af 2-(4-(diphenylmethylen)- l-piperidinyl)- eddikesyrer eller farmaceutisk acceptable salte heraf | |
NZ198748A (en) | Piperidine derivatives and pharmaceutical compositions | |
AU600378B2 (en) | Piperidine derivatives, their preparation and their application in therapy | |
NO177094B (no) | Nye N-alkylerte 1,4-dihydropyridindikarboksylsyreestere samt deres anvendelse i legemidler | |
JPH08501548A (ja) | 抗精神病薬としての環状ベンジルアミノ、ベンジルアミド及びベンジルイミド誘導体 | |
SK10912001A3 (sk) | Derivát benzamidu a liečivo obsahujúce túto látku | |
JPH03120271A (ja) | 抗虚血活性を有するフェニルアルキルアミン誘導体 | |
ES2912409T3 (es) | Intermedios y procesos para la preparación de linagliptina y sus sales | |
US4438121A (en) | Isoquinoline amidoxime derivatives | |
AU597187B2 (en) | 2-{ (4-piperidyl)methyl}benzofuro{2,3-c}pyridine derivatives, their preparation and their application in therapy | |
JPH0319236B2 (enrdf_load_html_response) |